VistaGen Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by VistaGen Therapeutics, Inc. on September 17, 2021. The filing details the voting results for three proposals submitted to security holders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The following matters were voted upon and approved by stockholders:
- Election of Directors: All seven nominees were elected to the Board of Directors. Notable vote counts included Jon S. Saxe (94,491,353 For) and Ann M. Cunningham (119,784,433 For).
- Equity Incentive Plan Amendment: Stockholders approved the amendment and restatement of the 2019 Omnibus Equity Incentive Plan. This action increases the number of shares authorized for issuance from 7.5 million to 18 million shares. The proposal received 108,327,165 votes For, 18,345,773 Against, and 291,464 Abstentions.
- Ratification of Auditors: The appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending March 31, 2022, was ratified. The proposal received 151,765,197 votes For, 6,773,836 Against, and 439,036 Abstentions.
Guidance, Outlook, and Risks
This filing does not contain management guidance, financial outlook, or specific risk factors. It references a transcript of closing remarks by CEO Shawn K. Singh as Exhibit 99.1, which is not considered "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the impact of the increased share authorization (from 7.5 million to 18 million) on potential future dilution.
- Review the definitive proxy statement filed on July 29, 2021, for detailed biographies of the newly elected directors and full terms of the equity plan amendment.
- Confirm the fiscal year-end date of March 31, 2022, for future financial reporting expectations.